Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 24.6 kDa. The protein migrates as 35-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Mouse CD16, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Biotinylated Mouse CD16, His,Avitag (Cat. No. FC6-M82E0) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Biotinylated Mouse CD16, His,Avitag (Cat. No. FC6-M82E0) captured on Biotin CAP- Series S Sensor Chip can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3) with an affinity constant of 0.345 μM as determined in a SPR assay (Biacore T200) (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $360.00
Price(USD) : $1565.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides | Details |
AFM-24 | AFM-24 | Phase 2 Clinical | Affimed | Solid tumours | Details |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
SAR445514 | SAR445514; SAR-445514; IPH6401/SAR514 | Phase 2 Clinical | Sanofi | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
FT-538 | FT-538 | Phase 2 Clinical | Fate Therapeutics Inc | Solid tumours; HIV Infections; Ovarian Neoplasms; Leukemia, Myeloid; Neoplasms; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute | Details |
GMA-161 | GMA-161 | Phase 1 Clinical | Sanofi, Macrogenics Inc | Purpura, Thrombocytopenic, Idiopathic | Details |
GTB-5550 | GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™ | Phase 1 Clinical | University Of Minnesota | Solid tumours | Details |
FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
GTB-3650 | GTB-3650; GTB-360; OXS-3350; OXS-C3550 | Phase 1 Clinical | Masonic Cancer Center, University Of Minnesota | Bone Marrow Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeiGene (Beijing) Co Ltd | Solid tumours; Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
SM-3321 | SM-3321; SM3321 | Phase 1 Clinical | Beijing StarMab BioMed Technology Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
FT-516 | FT-516 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Ovarian Neoplasms; Lymphoma, B-Cell; Solid tumours; Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms | Details |
This web search service is supported by Google Inc.